journal article·2025-12-23Open access

Coupling Adoptive Cell Therapy with Boron Neutron Capture Therapy: Using Functional Tumor-Infiltrating Lymphocytes for Tumor Delivery of Boron Carbide Nanoparticles

Maria Paola Demichelis, Patrizia Sommi, Nicola Romanini, Agustina Portu, Mario Gadan, Silva Bortolussi, Ian Postuma, Alberto Casu, Andrea Falqui, Maria Elisabetta Federica Palamà, Silvia Scaglione, Francesca Tauceri, Giovanni Paganelli, Marcella Tazzari, Umberto Anselmi-Tamburini

ACS Nano· Volume 19· Issue 50

Abstract

High Resolution Image Download MS PowerPoint Slide Nanomedicine offers promising strategies for targeted drug delivery, imaging, and molecular-level therapies. However, the clinical translation of nanomedicine has often been hindered by the complex interactions of nanoparticles (NPs) with biological systems. This study investigates a cell-based delivery platform designed to overcome some of these limitations, using clinical-grade tumor-infiltrating lymphocytes (TILs) as biological carriers of boron carbide (B 4 C) NPs in boron neutron capture therapy (BNCT). Biological vectors, such as TILs, could enable selective tumor targeting, leading to highly localized 10 B levels and minimizing off-target accumulation. We evaluated the uptake and retention of composite Fe 2 O 3 –B 4 C NPs (FeBNPs) using both immortalized Jurkat T cells and primary human TILs. Both cell types efficiently internalized FeBNPs without cytotoxic effects, maintained their functionalities, and retained the boron-rich NPs for up to 72 h. Imaging confirmed intracellular localization, and neutron autoradiography demonstrated that TILs accumulated sufficient 10 B for therapeutic efficacy, eliminating the need for isotopically enriched compounds like L-4-boronophenylalanine (BPA) or sodium borocaptate (BSH). Coculture experiments with Jurkat and HeLa cells confirmed that lymphocyte-delivered boron could mediate localized radiation damage via neutron capture. These findings support the concept of TILs as “Trojan Horses” for boron delivery, allowing for overcoming traditional barriers in NP-based therapies and taking advantage of their innate tumor-homing ability. This approach not only enhances BNCT selectivity and efficacy but also supports the integration of nanomedicine with adoptive cell therapy in a combined cancer treatment framework.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Boron Compounds in Chemistry · Boron and Carbon Nanomaterials Research · Organoboron and organosilicon chemistry

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Physics “Alessandro Volta”, University of Pavia, Via A. Bassi 6, 27100 Pavia, Italy

Unit of Pavia, National Institute of Nuclear Physics (INFN), Via A. Bassi 6, 27100 Pavia, Italy

Department of Molecular Medicine, University of Pavia, Via Forlanini 6, 27100 Pavia, Italy

Advanced Cellular Therapies and Rare Tumors Unit

IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”

National Atomic Energy Commission (CNEA)

National Scientific and Technological Research Council (CONICET)

School of Science & Technology

National University of San Martín (UNSAM)

Department of Physics “Aldo Pontremoli”, University of Milan, Via Celoria 16, 20133 Milan, Italy

React4life

National Research Council

IEIIT Institute

General and Oncological Surgery

Morgagni-Pierantoni Hospital

Nuclear Medicine Operative Unit

Department of Chemistry, University of Pavia, V.le Taramelli 12, 27100 Pavia, Italy

University of Ferrara

Funding

AdvaNced Technologies for Human-centrEd Medicine

References (51)

Show source-provided references
1. 10.1177/15330346030020050210.1177/153303460300200502 ↗
2. 10.1002/cac2.1208910.1002/cac2.12089 ↗
3. 10.1016/j.rpor.2014.11.00410.1016/j.rpor.2014.11.004 ↗
4. 10.1016/j.apradiso.2020.10931510.1016/j.apradiso.2020.109315 ↗
5. 10.1186/s40880-018-0299-710.1186/s40880-018-0299-7 ↗
6. 10.1016/j.ccr.2019.21313910.1016/j.ccr.2019.213139 ↗
7. 10.1093/jrr/rrt09810.1093/jrr/rrt098 ↗
8. 10.1007/s12553-024-00862-710.1007/s12553-024-00862-7 ↗
9. 10.3109/09553002.2014.99538110.3109/09553002.2014.995381 ↗
10. 10.1016/j.nimb.2011.11.04310.1016/j.nimb.2011.11.043 ↗
11. 10.3390/genes1401012710.3390/genes14010127 ↗
12. 10.3390/pharmaceutics1404076110.3390/pharmaceutics14040761 ↗
13. Xuan S. · 2018
14. 10.3390/ma1619653410.3390/ma16196534 ↗
15. 10.1080/17458080.2019.169217810.1080/17458080.2019.1692178 ↗
16. 10.3390/life1302042910.3390/life13020429 ↗
17. Greim J. · 2006
18. 10.1016/B978-0-12-803581-8.11638-810.1016/B978-0-12-803581-8.11638-8 ↗
19. 10.4028/www.scientific.net/KEM.56-57.5910.4028/www.scientific.net/KEM.56-57.59 ↗
20. 10.1070/RC2012v081n06ABEH00428710.1070/RC2012v081n06ABEH004287 ↗
21. 10.1016/j.msea.2006.08.06810.1016/j.msea.2006.08.068 ↗
22. 10.1038/nrc.2016.10810.1038/nrc.2016.108 ↗
23. 10.1056/NEJMoa221023310.1056/NEJMoa2210233 ↗
24. 10.1172/JCI11844310.1172/JCI118443 ↗
25. 10.3390/applnano502000410.3390/applnano5020004 ↗
26. 10.1039/C9TB01955C10.1039/C9TB01955C ↗
27. 10.1016/S1369-7021(11)70163-810.1016/S1369-7021(11)70163-8 ↗
28. 10.1016/j.eurpolymj.2005.11.02310.1016/j.eurpolymj.2005.11.023 ↗
29. 10.3390/cancers1516409110.3390/cancers15164091 ↗
30. Barth R. F. · J. Neuro-Oncol. · 1997 · 33 · 310.1023/A:1005783531660 ↗
31. 10.1017/S143192761501434810.1017/S1431927615014348 ↗
32. 10.1038/labinvest.2017.2510.1038/labinvest.2017.25 ↗
33. 10.1038/bjc.2013.55710.1038/bjc.2013.557 ↗
34. 10.1097/CJI.0b013e3181fb045d10.1097/CJI.0b013e3181fb045d ↗
35. 10.1002/1521-4141(200206)32:6<1792::AID-IMMU1792>3.0.CO;2-010.1002/1521-4141(200206)32:6<1792::AID-IMMU1792>3.0.CO;2-0 ↗
36. 10.1667/RR2156.110.1667/RR2156.1 ↗
37. 10.1038/s41598-022-06938-610.1038/s41598-022-06938-6 ↗
38. 10.1039/C7TB00038C10.1039/C7TB00038C ↗
39. 10.1128/IAI.00930-1910.1128/IAI.00930-19 ↗
40. 10.1186/s12951-024-02397-510.1186/s12951-024-02397-5 ↗
41. Kircher M. F. · Cancer Res. · 2003 · 63 · 6838
42. 10.3390/cells1004080810.3390/cells10040808 ↗
43. 10.1158/0008-5472.CAN-16-317210.1158/0008-5472.CAN-16-3172 ↗
44. 10.1016/j.ejmp.2021.08.01010.1016/j.ejmp.2021.08.010 ↗
45. 10.1016/j.acthis.2018.02.00510.1016/j.acthis.2018.02.005 ↗
46. 10.1016/j.rpor.2015.10.00610.1016/j.rpor.2015.10.006 ↗
47. 10.1016/j.radphyschem.2020.10893610.1016/j.radphyschem.2020.108936 ↗
48. 10.1017/S143192761901505810.1017/S1431927619015058 ↗
49. 10.1097/00002371-200307000-0000510.1097/00002371-200307000-00005 ↗
50. 10.1097/CJI.0b013e31824e801f10.1097/CJI.0b013e31824e801f ↗
51. 10.1158/2326-6066.CIR-17-046710.1158/2326-6066.CIR-17-0467 ↗